
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is well-positioned for long-term growth with its expanding subscriber base, international expansion efforts, successful partnerships, and investments in new initiatives. However, the company may face challenges such as regulatory changes and competition in the market, which may impact their adjusted EBITDA in the short term. Nonetheless, its strong financials and potential for $1B in revenue make it a promising investment opportunity for the future.
Bears say
Hims & Hers Health is a prominent direct-to-consumer telehealth company that offers a wide range of healthcare products and services through its digital platform. Despite strong revenue growth and partnerships with companies like Novo Nordisk and Eucalyptus, the company's financials have been impacted by international expansion, investments in new therapies and AI, and strategic shifts in its weight loss offerings. The company's DTC-focused model relies on maintaining strong marketing yields and customer retention, which could be challenged by potential regulatory changes that may limit their ability to offer personalized compounded medications. With a negative outlook, the analyst values the company's FY26 estimates at an EV/sales multiple of 3.4x, lower than the 20%+ tech comp group average of 5.2x indicating potential risk for investors.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares